Nicotine dependence: neuropharmacology in monkeys

尼古丁依赖：猴子的神经药理学

基本信息

批准号：
8890817
负责人：
Lance R McMahon
金额：
$ 33.13万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-04-01 至 2019-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8890817
关键词：
Acetylcholine Acetylcholinesterase Inhibitors Acute Adult Affinity Agonist Attenuated Behavioral Assay Binding Biological Assay Cancer Etiology Cardiovascular Diseases Cause of Death Cessation of life Chantix Chemicals Chronic Cigarette Clinical Clinical effectiveness Data Dimensions Discrimination Disease Effectiveness Face Funding Galantamine Grant Health Heart Individual Lead Ligands Lung Lung diseases Macaca mulatta Malignant Neoplasms Monkeys Neuropharmacology Nicotine Nicotine Dependence Nicotinic Receptors Nose Pharmaceutical Preparations Pharmacology Pharmacotherapy Pre-Clinical Model Public Health Recording of previous events Saline Smoking Smoking Behavior Stimulus Testing Time Tobacco smoke Tobacco use United States Withholding Treatment Work acetylcholine receptor agonist base cigarette smoking cytisine deprivation drug discrimination epibatidine in vivo interest nicotine abuse nicotine replacement nonhuman primate novel preclinical study premature receptor reinforcer research study smoking cessation varenicline

项目摘要

DESCRIPTION (provided by applicant): Cigarette smoking is a leading cause of cancer as well as cardiovascular and respiratory disease and is the leading preventable cause of death in the United States. Many factors contribute to cigarette smoking, including nicotine, other chemicals in tobacco smoke, and conditioned reinforcers. This competing continuation of an R01 proposal focuses on nicotine and nicotinic acetylcholine receptors (nAChR) as critical determinants of smoking behavior and smoking cessation pharmacotherapy. Drug discrimination assays in rhesus monkeys will be used to examine the impact of drug history (nicotine treatment) on the effects of low and high efficacy nAChR agonists and allosteric nAChR modulators. In the previous funding period, whereas varenicline substituted for the discriminative stimulus effects of nicotine administered acutely, varenicline was no longer able to substitute for nicotine under conditions relevant to the clinical setting (i.e., chronic nicotin treatment). Aim 1 examines nAChR efficacy (intrinsic activity) as the critical determinant of the ability of nAChR agonists to mimic the discriminative stimulus effects of nicotine. Novel nAChR agonists with higher efficacy than varenicline will be examined for their ability to mimic the effects of nicotine during chronic treatment, whereas novel nAChR agonists with lower efficacy than varenicline will be examined for their ability to antagonize the effects of nicotine during chronic nicotine treatment. In a second experiment conducted during the previous funding period, the dual positive allosteric nAChR modulator and competitive, reversible AChE inhibitor galantamine fully substituted for the discriminative stimulus effects of nicotine in rhesus monkeys. Aim 2 compares the effects of orthosteric and allosteric ligands at nAChR and, in particular, examines the potential of allosteric nAChR modulators to modify the effects of nicotine. Both positive and negative allosteric nAChR modulators with selectivity for subtypes of nAChR will be tested under acute and chronic nicotine treatment conditions. Although currently available pharmacotherapies for smoking cessation are effective in some, there is considerable margin for improvement. These pre-clinical studies will help identify pharmacologic dimensions and novel directions upon which to develop novel medications that could further reduce the devastating consequences of cigarette smoking.

描述（由申请人提供）：吸烟是癌症以及心血管和呼吸系统疾病的主要原因，也是美国主要的可预防死亡原因。许多因素都会导致吸烟，包括尼古丁、烟草烟雾中的其他化学物质和条件强化物。 R01 提案的这一竞争性延续重点关注尼古丁和烟碱乙酰胆碱受体 (nAChR) 作为吸烟行为和戒烟药物治疗的关键决定因素。恒河猴的药物辨别试验将用于检查药物史（尼古丁治疗）对低效和高效 nAChR 激动剂和变构 nAChR 调节剂的影响。在上一个资助期间，伐尼克兰替代了急性尼古丁的歧视性刺激作用，但在与临床环境相关的条件下（即慢性尼古丁治疗），伐尼克兰不再能够替代尼古丁。目标 1 检查 nAChR 功效（内在活性）作为 nAChR 激动剂模拟尼古丁区别性刺激作用能力的关键决定因素。将检查比伐尼克兰功效更高的新型 nAChR 激动剂在长期治疗期间模拟尼古丁作用的能力，而将检查比伐尼克兰功效较低的新型 nAChR 激动剂在长期尼古丁治疗期间拮抗尼古丁作用的能力。在上一个资助期间进行的第二个实验中，双重正向变构 nAChR 调节剂和竞争性可逆 AChE 抑制剂加兰他敏完全取代了尼古丁对恒河猴的歧视性刺激作用。目标 2 比较了正构配体和变构配体对 nAChR 的作用，特别是检查了变构 nAChR 调节剂改变尼古丁作用的潜力。对 nAChR 亚型具有选择性的正向和负向变构 nAChR 调节剂将在急性和慢性尼古丁治疗条件下进行测试。尽管目前可用的戒烟药物疗法对某些人有效，但仍有相当大的改进空间。这些临床前研究将有助于确定药理学维度和新方向，以开发新药物，进一步减少吸烟的破坏性后果。